摘要
目的:探讨瑞芬太尼预处理对急性脑缺血损伤大鼠炎性因子的影响。方法:将60只SD大鼠随机分为空白组,假手术组,急性脑缺血组,瑞芬太尼预处理组4组。除空白组外,各组均根据术后3个不同处死取样时间点6 h、12 h、24 h再进一步分为3个亚组,每个亚组6只。造模后对大鼠进行神经功能缺损评分,HE染色观察大鼠脑组织神经元的病理形态变化,TTC染色观察脑梗死体积,采用RT-PCR检测TNF-α、IL-6、IL-8的表达水平。结果:(1)HE染色,空白组、假手术组大鼠脑组织病理形态无明显改变,急性脑缺血组大鼠神经元结构明显受损,瑞芬太尼预处理组较急性脑缺血组在各时间点神经元受损减轻;(2)TTC染色,瑞芬太尼预处理组灰白色脑梗死面积较脑缺血组损伤明显减少(P<0.05)。(3)RT-PCR检测结果,空白组和假手术组的TNF-α、IL-6、IL-8的表达水平在各时间差异无统计学意义(P>0.05),与脑缺血组比较,瑞芬太尼预处理组TNF-α、IL-6、IL-8的表达水平在各时间点明显降低(P<0.05)。结论:瑞芬太尼预处理通过降低脑缺血损伤后炎性因子表达而具有脑保护作用。
Objective:To investigate the effect of remifentanil preconditioning on inflammatory factors in rats with acute cerebral ischemia.Methods:60 SD rats were randomly divided into the blank group,sham operation group,ischemic brain injury group,and remifentanil pretreatment group.Except the blank group,each group was divided into 3 subgroups(6 in each group)at the time point of 6 h,12 h,and 24 h,6 per subgroup.After modeling,the rats were scored for neurologic deficit,the pathological changes of neurons inra brain were observed by TTC staining,and TNT-α,IL-6,IL-8 were detected by RT-PCR.Results:(1)HE staining,the brain tissue of the normal control group and sham operation group had no significant change in pathological morphology rats.Compared with ischemic brain injury group,the remifentanil pretreatment group damage of nerve cell was reduced at all time.(2)TTC staining,compared with ischemic brain injury group,the area of gray-white cerebral infarction in the pretreatment with remifentanil was significantly reduced(P<0.05).(3)RT-PCR:The expression levels of TNF-α,IL-6,and IL-8 in the blank and sham groups did not change significantly across time(P>0.05);as compared with ischemic brain injury group,the expression of remifentanil pretreatment group that TNF-α,IL-6,IL-8 have decreased significantly at all time(P<0.05).Conclusions:Remifentanil pretreatmen can reduce cerebral ischemia reperfusion injury and play a role of brain protection.
作者
周金凤
曾宪晶
刘姝
袁金华
龙菲
ZHOU Jinfeng;ZENG Xianjing;LIU Shu;YUAN Jinhua;LONG Fei(Affiliated Hospital of Jinggangshan University,Ji'an Jiangxi 343000,China.)
出处
《药品评价》
CAS
2022年第7期399-402,共4页
Drug Evaluation
基金
江西省科技计划项目(2020071B)
江西省中医药管理局科技计划项目(2019A149)
江西省卫生健康委员会科技计划项目(20203792)。